Matches in SemOpenAlex for { <https://semopenalex.org/work/W4379280595> ?p ?o ?g. }
Showing items 1 to 78 of
78
with 100 items per page.
- W4379280595 endingPage "e21020" @default.
- W4379280595 startingPage "e21020" @default.
- W4379280595 abstract "e21020 Background: Double-dose icotinib has been proven effective and well tolerated for advanced NSCLC patients with the Epidermal Growth Factor Receptor (EGFR) L858R mutation. For the same patients, the excellent efficacy of bevacizumab combined with erlotinib has been proven in previous studies. In this study, we would investigate the efficacy of the combined therapy bevacizumab and double-dose icotinib for advanced NSCLC patients with EGFR L858R mutation. Methods: 35 patients diagnosed from September 2, 2021 to September 28, 2022 were enrolled in this study and 5 patients were excluded for analysis due to missing efficacy evaluation data. All patients were treated with intravenous bevacizumab (15mg / kg) combined with oral double-dose icotinib (250mg, tid). The primary endpoint was progression-free survival (PFS), and the secondary endpoints were safety, efficacy, and overall survival (OS). Results: Among the 35 patients, 12 were male and 23 were female. The median age at diagnosis was 66. Eight patients were diagnosed with brain metastases. All of the patients have EGFR L858R mutation, and 14 patients were with other coexisting mutations. To the data of December 31, 2022, the median follow-up time was 10 months (range: 3 to 18 months). For 30 patients with complete efficacy evaluation data, 20 patients achieved partial responses (PR), 9 patients had stable disease (SD), and 1 patient developed progress disease (PD). The objective response rate (ORR) was 66.7%, the disease control rate (DCR) was 96.7%, and the median PFS was 14.8 months. For adverse reaction evaluation, the grade 3 adverse events were albuminuria (n = 1) and hepatotoxicity (n = 1). Other adverse events were grade 1-2, mainly oral mucositis, rash, diarrhea and hypertension. Conclusions: The combination of bevacizumab with double-dose icotinib is an effective and relatively safe treatment for advanced NSCLC patients with EGFR L858R mutation. Further exploration will provide more evidence for this type of treatment. Clinical trial information: NCT05263947 ." @default.
- W4379280595 created "2023-06-05" @default.
- W4379280595 creator A5008675881 @default.
- W4379280595 creator A5063457276 @default.
- W4379280595 creator A5064729480 @default.
- W4379280595 creator A5065506624 @default.
- W4379280595 creator A5068763909 @default.
- W4379280595 creator A5077880789 @default.
- W4379280595 creator A5082367544 @default.
- W4379280595 creator A5086529957 @default.
- W4379280595 creator A5092083111 @default.
- W4379280595 date "2023-06-01" @default.
- W4379280595 modified "2023-10-17" @default.
- W4379280595 title "Effect of bevacizumab plus double dose icotinib on advanced non-small cell lung cancer with EGFR L858R mutation." @default.
- W4379280595 doi "https://doi.org/10.1200/jco.2023.41.16_suppl.e21020" @default.
- W4379280595 hasPublicationYear "2023" @default.
- W4379280595 type Work @default.
- W4379280595 citedByCount "0" @default.
- W4379280595 crossrefType "journal-article" @default.
- W4379280595 hasAuthorship W4379280595A5008675881 @default.
- W4379280595 hasAuthorship W4379280595A5063457276 @default.
- W4379280595 hasAuthorship W4379280595A5064729480 @default.
- W4379280595 hasAuthorship W4379280595A5065506624 @default.
- W4379280595 hasAuthorship W4379280595A5068763909 @default.
- W4379280595 hasAuthorship W4379280595A5077880789 @default.
- W4379280595 hasAuthorship W4379280595A5082367544 @default.
- W4379280595 hasAuthorship W4379280595A5086529957 @default.
- W4379280595 hasAuthorship W4379280595A5092083111 @default.
- W4379280595 hasConcept C121608353 @default.
- W4379280595 hasConcept C126322002 @default.
- W4379280595 hasConcept C143998085 @default.
- W4379280595 hasConcept C197934379 @default.
- W4379280595 hasConcept C203092338 @default.
- W4379280595 hasConcept C2776256026 @default.
- W4379280595 hasConcept C2776694085 @default.
- W4379280595 hasConcept C2777802072 @default.
- W4379280595 hasConcept C2778087573 @default.
- W4379280595 hasConcept C2778822529 @default.
- W4379280595 hasConcept C2779438470 @default.
- W4379280595 hasConcept C2780580887 @default.
- W4379280595 hasConcept C535046627 @default.
- W4379280595 hasConcept C71924100 @default.
- W4379280595 hasConcept C90924648 @default.
- W4379280595 hasConceptScore W4379280595C121608353 @default.
- W4379280595 hasConceptScore W4379280595C126322002 @default.
- W4379280595 hasConceptScore W4379280595C143998085 @default.
- W4379280595 hasConceptScore W4379280595C197934379 @default.
- W4379280595 hasConceptScore W4379280595C203092338 @default.
- W4379280595 hasConceptScore W4379280595C2776256026 @default.
- W4379280595 hasConceptScore W4379280595C2776694085 @default.
- W4379280595 hasConceptScore W4379280595C2777802072 @default.
- W4379280595 hasConceptScore W4379280595C2778087573 @default.
- W4379280595 hasConceptScore W4379280595C2778822529 @default.
- W4379280595 hasConceptScore W4379280595C2779438470 @default.
- W4379280595 hasConceptScore W4379280595C2780580887 @default.
- W4379280595 hasConceptScore W4379280595C535046627 @default.
- W4379280595 hasConceptScore W4379280595C71924100 @default.
- W4379280595 hasConceptScore W4379280595C90924648 @default.
- W4379280595 hasIssue "16_suppl" @default.
- W4379280595 hasLocation W43792805951 @default.
- W4379280595 hasOpenAccess W4379280595 @default.
- W4379280595 hasPrimaryLocation W43792805951 @default.
- W4379280595 hasRelatedWork W1835621121 @default.
- W4379280595 hasRelatedWork W2015910003 @default.
- W4379280595 hasRelatedWork W2017389411 @default.
- W4379280595 hasRelatedWork W2037355330 @default.
- W4379280595 hasRelatedWork W2060263774 @default.
- W4379280595 hasRelatedWork W2186047679 @default.
- W4379280595 hasRelatedWork W2340863814 @default.
- W4379280595 hasRelatedWork W2414367275 @default.
- W4379280595 hasRelatedWork W2978946191 @default.
- W4379280595 hasRelatedWork W4307234767 @default.
- W4379280595 hasVolume "41" @default.
- W4379280595 isParatext "false" @default.
- W4379280595 isRetracted "false" @default.
- W4379280595 workType "article" @default.